Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue

详细信息查看全文

作者：Jeffrey R Shuster (1)
Raymond S Lance (2)
Dean A Troyer (3)
刊名：BMC Clinical Pathology
出版年：2011
出版时间：December 2011
年：2011
卷：11
期：1
全文大小：525KB
参考文献：1. Parikh K, Peppelenbosch MP: Kinome profiling of clinical cancer specimens.strong> / Cancer Res 70strong>(7):strong>2575鈥?578.
2. Henson DE: Back to the drawing board on immunohistochemistry and predictive factors.strong> / J Natl Cancer Inst 2005,97strong>(24):strong>1796鈥?797. ss="external" href="http://dx.doi.org/10.1093/jnci/dji449">CrossRef
3. Rudiger T, Hofler H, Kreipe HH, Nizze H, Pfeifer U, Stein H, Dallenbach FE, Fischer HP, Mengel M, von Wasielewski R, Muller-Hermelink HK: Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists.strong> / Am J Surg Pathol 2002,26strong>(7):strong>873鈥?82. ss="external" href="http://dx.doi.org/10.1097/00000478-200207000-00005">CrossRef
4. Rhodes A, Jasani B, Balaton AJ, Miller KD: Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.strong> / J Clin Pathol 2000,53strong>(4):strong>292鈥?01. ss="external" href="http://dx.doi.org/10.1136/jcp.53.4.292">CrossRef
5. Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A: The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab.strong> / Am J Clin Pathol 2004,122strong>(1):strong>51鈥?0. ss="external" href="http://dx.doi.org/10.1309/E9B55JYHD84L8Y17">CrossRef
6. Fox CH, Johnson FB, Whiting J, Roller PP: Formaldehyde fixation.strong> / J Histochem Cytochem 1985,33strong>(8):strong>845鈥?53. ss="external" href="http://dx.doi.org/10.1177/33.8.3894502">CrossRef
7. Dimenstein IB: A Pragmatic Approach to Formalin Safety in Anatomical Pathology.strong> / Labmed 2009, 40:strong>740鈥?46.
8. Gillespie JW, Best CJ, Bichsel VE, Cole KA, Greenhut SF, Hewitt SM, Ahram M, Gathright YB, Merino MJ, Strausberg RL, Epstein JI, Hamilton SR, Gannot G, Baibakova GV, Calvert VS, Flaig MJ, Chuaqui RF, Herring JC, Pfeifer J, Petricoin EF, Linehan WM, Duray PH, Bova GS, Emmert-Buck MR: Evaluation of non-formalin tissue fixation for molecular profiling studies.strong> / Am J Pathol 2002,160strong>(2):strong>449鈥?57. ss="external" href="http://dx.doi.org/10.1016/S0002-9440(10)64864-X">CrossRef
9. Ahram M, Flaig MJ, Gillespie JW, Duray PH, Linehan WM, Ornstein DK, Niu S, Zhao Y, Petricoin EF, Emmert-Buck MR: Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications.strong> / Proteomics 2003,3strong>(4):strong>413鈥?21. ss="external" href="http://dx.doi.org/10.1002/pmic.200390056">CrossRef
10. Cox ML, Schray CL, Luster CN, Stewart ZS, Korytko PJ, KN MK, Paulauskis JD, Dunstan RW: Assessment of fixatives, fixation, and tissue processing on morphology and RNA integrity.strong> / Exp Mol Pathol 2006,80strong>(2):strong>183鈥?91. ss="external" href="http://dx.doi.org/10.1016/j.yexmp.2005.10.002">CrossRef
11. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics.strong> / CA Cancer J Clin 2010,60strong>(5):strong>277鈥?00. ss="external" href="http://dx.doi.org/10.3322/caac.20073">CrossRef
12. Hernandez J, Thompson IM: Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.strong> / Cancer 2004,101strong>(5):strong>894鈥?04. ss="external" href="http://dx.doi.org/10.1002/cncr.20480">CrossRef
13. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A: Screening and prostate-cancer mortality in a randomized European study.strong> / N Engl J Med 2009,360strong>(13):strong>1320鈥?328. ss="external" href="http://dx.doi.org/10.1056/NEJMoa0810084">CrossRef
14. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD: Mortality results from a randomized prostate-cancer screening trial.strong> / N Engl J Med 2009,360strong>(13):strong>1310鈥?319. ss="external" href="http://dx.doi.org/10.1056/NEJMoa0810696">CrossRef
15. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, / et al.: The genomic complexity of primary human prostate cancer.strong> / Nature 470strong>(7333):strong>214鈥?20.
16. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F: Insignificant prostate cancer and active surveillance: from definition to clinical implications.strong> / Eur Urol 2009,55strong>(6):strong>1321鈥?330. ss="external" href="http://dx.doi.org/10.1016/j.eururo.2009.02.028">CrossRef
17. Miocinovic R, Jones JS, Pujara AC, Klein EA, Stephenson AJ: Acceptance and Durability of Surveillance as a Management Choice in Men with Screen-Detected, Low-Risk Prostate Cancer: Improved Outcomes with Stringent Enrollment Criteria.strong> / Urology 2011,77strong>(4):strong>980鈥?84. ss="external" href="http://dx.doi.org/10.1016/j.urology.2010.09.063">CrossRef
18. O'Toole S A, Selinger CI, Millar EK, Lum T, Beith JM: Molecular assays in breast cancer pathology.strong> / Pathology 43strong>(2):strong>116鈥?27.
19. Kelley RK, Van Bebber SL, Phillips KA, Venook AP: Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.strong> / J Natl Compr Canc Netw 9strong>(1):strong>13鈥?5.
20. Turaga K, Acs G, Laronga C: Gene expression profiling in breast cancer.strong> / Cancer Control 17strong>(3):strong>177鈥?82.
21. Troyer DA, Lucia MS, de Bruine AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW: Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies.strong> / Cancer Epidemiol Biomarkers Prev 2009,18strong>(10):strong>2717鈥?722. ss="external" href="http://dx.doi.org/10.1158/1055-9965.EPI-09-0068">CrossRef
22. Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J, Astacio T, Canning S, Quijano J, Guinto W, Leibovich BC, Nelson JB, Vargo J, Wang Y, Wuxiong C: Multicenter evaluation of an investigational prostate cancer methylation assay.strong> / J Urol 2009,182strong>(3):strong>1186鈥?193. ss="external" href="http://dx.doi.org/10.1016/j.juro.2009.05.003">CrossRef
23. Hoque MO: DNA methylation changes in prostate cancer: current developments and future clinical implementation.strong> / Expert Rev Mol Diagn 2009,9strong>(3):strong>243鈥?57. ss="external" href="http://dx.doi.org/10.1586/erm.09.10">CrossRef
24. Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andren O, Eisenstein A, Holmberg L, Huang W, Kantoff PW, Kim R, Perner S, Stampfer MJ, Johansson JE, Rubin MA: Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort.strong> / Cancer Epidemiol Biomarkers Prev 2008,17strong>(7):strong>1682鈥?688. ss="external" href="http://dx.doi.org/10.1158/1055-9965.EPI-08-0044">CrossRef
25. Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, Albertsen P, Costa J, Cordon-Cardo C: Personalized prediction of tumor response and cancer progression on prostate needle biopsy.strong> / J Urol 2009,182strong>(1):strong>125鈥?32. ss="external" href="http://dx.doi.org/10.1016/j.juro.2009.02.135">CrossRef
26. Donovan MJ, Hamann S, Clayton M, Khan FM, Sapir M, Bayer-Zubek V, Fernandez G, Mesa-Tejada R, Teverovskiy M, Reuter VE, Scardino PT, Cordon-Cardo C: Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy.strong> / J Clin Oncol 2008,26strong>(24):strong>3923鈥?929. ss="external" href="http://dx.doi.org/10.1200/JCO.2007.15.3155">CrossRef
27. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.strong> / Nature 2009,457strong>(7231):strong>910鈥?14. ss="external" href="http://dx.doi.org/10.1038/nature07762">CrossRef
28. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J: Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues.strong> / Magn Reson Med 2008,60strong>(3):strong>510鈥?16. ss="external" href="http://dx.doi.org/10.1002/mrm.21694">CrossRef
29. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J: Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy.strong> / Magn Reson Med 2008,60strong>(1):strong>33鈥?0. ss="external" href="http://dx.doi.org/10.1002/mrm.21647">CrossRef
30. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, Sullivan H, Hedlund T, Crawford ED: The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions.strong> / Prostate 2008,68strong>(6):strong>620鈥?28. ss="external" href="http://dx.doi.org/10.1002/pros.20727">CrossRef
31. Mueller-Lisse UG, Scherr MK: Proton MR spectroscopy of the prostate.strong> / Eur J Radiol 2007,63strong>(3):strong>351鈥?60. ss="external" href="http://dx.doi.org/10.1016/j.ejrad.2007.06.024">CrossRef
32. Jordan KW, Cheng LL: NMR-based metabolomics approach to target biomarkers for human prostate cancer.strong> / Expert Rev Proteomics 2007,4strong>(3):strong>389鈥?00. ss="external" href="http://dx.doi.org/10.1586/14789450.4.3.389">CrossRef
33. Costello LC, Franklin RB: The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.strong> / Mol Cancer 2006, 5:strong>17鈥?9. ss="external" href="http://dx.doi.org/10.1186/1476-4598-5-17">CrossRef
34. Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ: Circulating tumor cells: evolving evidence and future challenges.strong> / Oncologist 2009,14strong>(11):strong>1070鈥?082. ss="external" href="http://dx.doi.org/10.1634/theoncologist.2009-0094">CrossRef
35. Eschwege P, Moutereau S, Droupy S, Douard R, Gala JL, Benoit G, Conti M, Manivet P, Loric S: Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study.strong> / Br J Cancer 2009,100strong>(4):strong>608鈥?10. ss="external" href="http://dx.doi.org/10.1038/sj.bjc.6604912">CrossRef
36. Okegawa T, Nutahara K, Higashihara E: Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.strong> / J Urol 2009,181strong>(3):strong>1091鈥?097. ss="external" href="http://dx.doi.org/10.1016/j.juro.2008.11.015">CrossRef
37. Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ: Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.strong> / J Urol 2008,179strong>(6):strong>2187鈥?191. ss="external" href="http://dx.doi.org/10.1016/j.juro.2008.01.102">CrossRef
38. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.strong> / Clin Cancer Res 2007,13strong>(23):strong>7053鈥?058. ss="external" href="http://dx.doi.org/10.1158/1078-0432.CCR-07-1506">CrossRef
39. Crehange G, Parfait S, Liegard M, Maingon P, Ben Salem D, Cochet A, Funes de la Vega M, Cormier L, Bonnetain F, Mirjolet C, Brunotte F, Walker PM: Tumor Volume and Metabolism of Prostate Cancer Determined by Proton Magnetic Resonance Spectroscopic Imaging at 3T Without Endorectal Coil Reveal Potential Clinical Implications in the Context of Radiation Oncology.strong> / Int J Radiat Oncol Biol Phys 2010,80strong>(4):strong>1087鈥?094. ss="external" href="http://dx.doi.org/10.1016/j.ijrobp.2010.03.007">CrossRef
40. Zakian KL, Shukla-Dave A, Ackerstaff E, Hricak H, Koutcher JA: 1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization.strong> / Cancer Biomark 2008,4strong>(4鈥?):strong>263鈥?76.
41. Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J: Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.strong> / Magn Reson Med 2006,55strong>(6):strong>1257鈥?264. ss="external" href="http://dx.doi.org/10.1002/mrm.20909">CrossRef
42. Schipper RG, Romijn JC, Cuijpers VM, Verhofstad AA: Polyamines and prostatic cancer.strong> / Biochem Soc Trans 2003,31strong>(2):strong>375鈥?80. ss="external" href="http://dx.doi.org/10.1042/BST0310375">CrossRef
43. Oyama T, Allsbrook WC, Kurokawa K, Matsuda H, Segawa A, Sano T, Suzuki K, Epstein JI: A comparison of interobserver reproducibility of Gleason grading of prostatic carcinoma in Japan and the United States.strong> / Arch Pathol Lab Med 2005,129strong>(8):strong>1004鈥?010.
44. Netto GJ, Eisenberger M, Epstein JI: Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologists: findings of TAX 3501 multinational clinical trial.strong> / Urology 77strong>(5):strong>1155鈥?160.
45. Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI: Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist.strong> / Hum Pathol 2001,32strong>(1):strong>81鈥?8. ss="external" href="http://dx.doi.org/10.1053/hupa.2001.21135">CrossRef
46. Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI: Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists.strong> / Hum Pathol 2001,32strong>(1):strong>74鈥?0. ss="external" href="http://dx.doi.org/10.1053/hupa.2001.21134">CrossRef
47. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.strong> / N Engl J Med 2004,351strong>(27):strong>2817鈥?826. ss="external" href="http://dx.doi.org/10.1056/NEJMoa041588">CrossRef
48. Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, Goralski TJ, Langmore JP, Raja RG, Williams PM, Palma JF, Warrington JA: Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue.strong> / Arch Pathol Lab Med 2008,132strong>(12):strong>1929鈥?935.
49. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE: Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.strong> / J Proteome Res 2009,8strong>(1):strong>113鈥?17. ss="external" href="http://dx.doi.org/10.1021/pr800545q">CrossRef
50. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ: SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.strong> / Clin Chem 2008,54strong>(1):strong>53鈥?0. ss="external" href="http://dx.doi.org/10.1373/clinchem.2007.091496">CrossRef
51. Vandromme MJ, Umphrey H, Krontiras H: Image-guided methods for biopsy of suspicious breast lesions.strong> / J Surg Oncol 103strong>(4):strong>299鈥?05.
52. Solomon SB, Zakowski MF, Pao W, Thornton RH, Ladanyi M, Kris MG, Rusch VW, Rizvi NA: Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.strong> / AJR Am J Roentgenol 194strong>(1):strong>266鈥?69.
53. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, / et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.strong> / N Engl J Med 2005,353strong>(16):strong>1659鈥?672. ss="external" href="http://dx.doi.org/10.1056/NEJMoa052306">CrossRef
54. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E: Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems.strong> / Anal Chem 2009,81strong>(16):strong>6656鈥?667. ss="external" href="http://dx.doi.org/10.1021/ac901536h">CrossRef
55. Dehaven CD, Evans AM, Dai H, Lawton KA: Organization of GC/MS and LC/MS metabolomics data into chemical libraries.strong> / J Cheminform 2010,2strong>(1):strong>9. ss="external" href="http://dx.doi.org/10.1186/1758-2946-2-9">CrossRef
56. The pre-publication history for this paper can be accessed here:ss="a-plus-plus">http://www.biomedcentral.com/1472-6890/11/14/prepub
作者单位：Jeffrey R Shuster (1)
Raymond S Lance (2)
Dean A Troyer (3)

1. The Biomarker Factory, 4307 Emperor Blvd, Ste 200, Durham, NC, USA
2. Dept of Urology, Eastern Virginia Medical School, Norfolk, VA, USA
3. Depts. Of Pathology and Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA

文摘

Background Histopathology is the standard method for cancer diagnosis and grading to assess aggressiveness in clinical biopsies. Molecular biomarkers have also been described that are associated with cancer aggressiveness, however, the portion of tissue analyzed is often processed in a manner that is destructive to the tissue. We present here a new method for performing analysis of small molecule biomarkers and histology in exactly the same biopsy tissue. Methods Prostate needle biopsies were taken from surgical prostatectomy specimens and first fixed, each in a separate vial, in 2.5 ml of 80% methanol:water. The biopsies were fixed for 24 hrs at room temperature and then removed and post-processed using a non-formalin-based fixative (UMFIX), embedded, and analyzed by hematoxylin and eosin (H&E) and by immunohistochemical (IHC) staining. The retained alcohol pre-fixative was analyzed for small molecule biomarkers by mass spectrometry. Results H&E analysis was successful following the pre-fixation in 80% methanol. The presence or absence of tumor could be readily determined for all 96 biopsies analyzed. A subset of biopsy sections was analyzed by IHC, and cancerous and non-cancerous regions could be readily visualized by PIN4 staining. To demonstrate the suitability for analysis of small molecule biomarkers, 28 of the alcohol extracts were analyzed using a mass spectrometry-based metabolomics platform. All extracts tested yielded successful metabolite profiles. 260 named biochemical compounds were detected in the alcohol extracts. A comparison of the relative levels of compounds in cancer containing vs. non-cancer containing biopsies showed differences for 83 of the compounds. A comparison of the results with prior published reports showed good agreement between the current method and prior reported biomarker discovery methods that involve tissue destructive methods. Conclusions The Molecular Preservation by Extraction and Fixation (mPREF) method allows for the analysis of small molecule biomarkers from exactly the same tissue that is processed for histopathology.

地址：北京市海淀区学院路29号邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700